A real world observational study to evaluate the rate of decline in renal function (eGFR) in Fabrazyme treated patients (16 years or older) matched 1:1 with a historical cohort of untreated patients
Latest Information Update: 23 Mar 2021
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- 23 Mar 2021 New trial record
- 12 Mar 2021 Results presented in a Sanofi media release.